Navigation Links
Study identifies potential new strategy to improve odds of corneal transplant acceptance
Date:12/30/2013

DALLAS Dec. 30, 2013 For the estimated 10 percent of patients whose bodies reject a corneal transplant, the odds of a second transplant succeeding are poor. All that could change, however, based on a UT Southwestern Medical Center study that has found a way to boost the corneal transplant acceptance rate.

In the study, researchers found that corneal transplants in mice were accepted 90 percent of the time when the action of an immune system molecule called interferon-gamma (IFN-γ) was blocked and when the mice shared the same major histocompatibility complex (MHC) genotype as the donor cornea. MHC matching is not typically done with human corneal transplants because of a high acceptance rate.

"Our findings indicate that neither MHC matching alone nor administration of anti-IFN-γ antibody alone enhances graft survival. However, we found that when MHC matching is combined with anti-IFN-γ therapy, long-term corneal transplant survival is almost guaranteed," said Dr. Jerry Niederkorn, Professor of Ophthalmology and Microbiology at UT Southwestern and senior author of the study.

The study findings, reported in the December issue of the American Journal of Transplantation, suggest an option to improve the odds of a subsequent corneal transplant's success for those patients whose first transplant was rejected.

More than 40,000 corneal transplants are performed annually in the United States, making this surgical procedure one of the most common and successful in transplantation. But out of that total, about 4,000 fail, with the recipient's body rejecting the corneal graft and requiring a second operation.

A surprising finding of the study was learning that IFN-γ can act both as an immune system suppressor or activator, depending on the context of the histocompatibility antigens perceived by the immune system, Dr. Niederkorn said. Earlier studies indicated that this molecule only activated immune system rejection of transplants and that disabling IFN-γ would improve the acceptance rate. But that was not necessarily the case; researchers found that when there was no MHC matching between the mice and the transplants, and IFN-γ was disabled, the transplant rejection rate was 100 percent.

"Under those conditions, IFN-γ was needed to maintain the T regulatory cells, which suppress the immune response," Dr. Niederkorn said.

Rather than recommend transplant matching and inactivation of IFN-γ for all first-time corneal transplant recipients, Dr. Niederkorn said this strategy would make most sense for those who have already rejected a cornea, or for those individuals believed to be at risk for a corneal transplant rejection. But before a clinical trial can be launched to verify the results obtained in mice, further study is needed.

"We are working to develop an IFN-γ antibody in eye-drop form," Dr. Niederkorn said. "Then we need to test whether this antibody will work in animal models."

Lead author of the study was Dr. Khrishen Cunnusamy, a former postdoctoral researcher in Dr. Niederkorn's lab and current UT Southwestern medical student.


'/>"/>

Contact: Debbie Bolles
debbie.bolles@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert  

Related medicine news :

1. New study: High mortality in Central Southern states most likely due to smoking
2. Contract Research Organization WCCT Global Announces Milestone for Clinical Study Completion
3. As Tylenol Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Finding that Acetaminophen Combined With Alcohol May Increase Risk for Kidney Damage
4. Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Notes Publication of New Study Questioning Cost, Benefits of Robotic Surgery
5. PDL-1 antibody could help immune system fight off influenza viral infection, study suggests
6. Study shows value of calcium scan in predicting heart attack, stroke among those considered at risk
7. Embargoed study: New quality, payment initiative positively impacts pediatric care
8. PM2.5 Monitor Industry in Global and China Regions 2013 Analysis in a New Study at DeepResearchReports.com
9. Austin Doctor Participates in Flu Vaccine Research Study in an Effort to Find More Effective Vaccines.
10. UV Technologies, LLC, Makers of UV-Aid® Release Results of Study Showing Photo-Oxidation Technology Highly Effective in Preventing Colds, Flu, and Ear Infections
11. Agein Corporation, a Leading Anti-Aging Company, Responds to Study Showing Personal Care Products a Possible Source of Harmful Parabens for Babies
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study identifies potential new strategy to improve odds of corneal transplant acceptance
(Date:8/22/2017)... ... 2017 , ... The Women’s Choice Award, a growing platform that gives a ... Women’s Choice Award. The identification by women of an effective new migraine relief ... are women. In a survey taken by the Women’s Choice Award organization, nine out ...
(Date:8/22/2017)... ... 2017 , ... Pivot Point Consulting, a ... the firm’s new Consulting Services Executive. Mr. Tisch will oversee all aspects of ... clients with initial vendor selection and pre-implementation planning through go-live support and post-live ...
(Date:8/22/2017)... ... , ... Nurses at Apple Rehab Watch Hill , a nursing and ... certification in Closed Pulse Irrigation™ (CPI) for wound care. This qualifies ... for Medicare and Medicaid Services, to have a CPI machine that will provide better ...
(Date:8/22/2017)... ... ... “Wilderness Voices”: a collection of poetry inspired by life on a Kentucky ... published author, Martha McKown, an ordained United Methodist minister with graduate degrees in Religious ... her older sisters studied High School literature. She loved the early English folk ...
(Date:8/22/2017)... ... ... “Glimpses Of Light”: is a unique and thought inspiring guide toward self-discovery ... published author, J.M. Shepherd, a writer, teacher, traveler, and metaphysician, the author has spent ... shares, “Love is one of the least understood and yet most sought-after pleasures known ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)... Fenita J. Caldwell is ... Lifetime Professional in the Field of Healthcare. Caldwell ... Pharmaceuticals, AG. Her skills and areas of expertise ... Fenita ... experience as a highly successful sales specialist in ...
(Date:8/2/2017)... 2017  Life Flight Network and PeaceHealth Oregon Network announced ... care and operational efficiency for patients at hospitals in ... Cottage Grove , and Florence, Oregon ... Life Flight Network work collaboratively to move patients who require ... a time sensitive emergency exists. ...
(Date:8/1/2017)... 2017   CerSci Therapeutics , a non-opioid drug ... , has received notice from the National Institute on ... (NIH) that it has been awarded a Direct-to-Phase II ... in 2017 with an additional $1,000,000 to follow in ... application of their lead non-opioid drug candidate CT-044 to ...
Breaking Medicine Technology: